AU2016265922B2 - A pharmaceutical co-crystal and use thereof - Google Patents

A pharmaceutical co-crystal and use thereof Download PDF

Info

Publication number
AU2016265922B2
AU2016265922B2 AU2016265922A AU2016265922A AU2016265922B2 AU 2016265922 B2 AU2016265922 B2 AU 2016265922B2 AU 2016265922 A AU2016265922 A AU 2016265922A AU 2016265922 A AU2016265922 A AU 2016265922A AU 2016265922 B2 AU2016265922 B2 AU 2016265922B2
Authority
AU
Australia
Prior art keywords
virus
cancer
cbcbp
crystal
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016265922A
Other languages
English (en)
Other versions
AU2016265922A1 (en
Inventor
Xiaozhong Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syn Nat Products Enterprise LLC
Original Assignee
Syn Nat Products Enterprise LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syn Nat Products Enterprise LLC filed Critical Syn Nat Products Enterprise LLC
Publication of AU2016265922A1 publication Critical patent/AU2016265922A1/en
Application granted granted Critical
Publication of AU2016265922B2 publication Critical patent/AU2016265922B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0086—Platinum compounds
    • C07F15/0093—Platinum compounds without a metal-carbon linkage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2016265922A 2015-05-18 2016-05-17 A pharmaceutical co-crystal and use thereof Ceased AU2016265922B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562163256P 2015-05-18 2015-05-18
US62/163,256 2015-05-18
PCT/US2016/032856 WO2016187191A1 (en) 2015-05-18 2016-05-17 A pharmaceutical co-crystal and use thereof

Publications (2)

Publication Number Publication Date
AU2016265922A1 AU2016265922A1 (en) 2017-12-07
AU2016265922B2 true AU2016265922B2 (en) 2021-05-20

Family

ID=57320544

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016265922A Ceased AU2016265922B2 (en) 2015-05-18 2016-05-17 A pharmaceutical co-crystal and use thereof

Country Status (9)

Country Link
US (1) US10751318B2 (cg-RX-API-DMAC7.html)
EP (1) EP3297624B1 (cg-RX-API-DMAC7.html)
JP (1) JP6851989B2 (cg-RX-API-DMAC7.html)
KR (1) KR20180008594A (cg-RX-API-DMAC7.html)
CN (1) CN108135877B (cg-RX-API-DMAC7.html)
AU (1) AU2016265922B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017024727A2 (cg-RX-API-DMAC7.html)
CA (1) CA2986136A1 (cg-RX-API-DMAC7.html)
WO (1) WO2016187191A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3297624B1 (en) 2015-05-18 2021-03-03 Syn-Nat Products Enterprise LLC A pharmaceutical co-crystal and use thereof
WO2016205785A1 (en) 2015-06-19 2016-12-22 Syn-Nat Products Enterprise LLC Pharmaceutical composition of carboplatin based co-crystals and use thereof
EP3297440A4 (en) 2015-06-19 2019-04-10 Syn-Nat Products Enterprise LLC COMPOSITION WITH CARBOPLATIN AND USE
CN107847521A (zh) 2015-06-25 2018-03-27 新纳特产品公司 药物共晶组合物及其用途
CN109053808B (zh) * 2017-06-21 2020-12-29 宋勤华 一种高纯度双环铂针状晶体的工业化制备方法
CN111356454B (zh) * 2017-11-21 2023-04-07 湖南湘源美东医药科技有限公司 含有双环铂的组合产品、其制备方法及其用途
CN116217628B (zh) * 2023-05-08 2023-07-14 华东理工常熟研究院有限公司 奥沙利铂Pt(IV)配合物的共晶及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090281319A1 (en) * 2006-01-30 2009-11-12 Platco Technologies (Proprietary) Limited Preparation of platinum (ii) complexes
WO2016205785A1 (en) * 2015-06-19 2016-12-22 Syn-Nat Products Enterprise LLC Pharmaceutical composition of carboplatin based co-crystals and use thereof
WO2016210418A1 (en) * 2015-06-25 2016-12-29 Syn-Nat Products Enterprise LLC Pharmaceutical co-crystal composition and use thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3290365A (en) * 1963-06-21 1966-12-06 Standard Oil Co Method of preparing cis-cyclobutane-1, 2-dicarboxylic acid
US5455270A (en) * 1993-08-11 1995-10-03 Bristol-Myers Squibb Co. Stabilized solutions of platinum(II) antitumor agents
KR100317473B1 (ko) 1999-05-11 2001-12-22 이계호 신규의 백금(ｉｖ)착제 및 그 제조방법
CN1121380C (zh) 2000-03-03 2003-09-17 北京兴大豪斯科技有限公司 一种抗肿瘤的双二羧酸二氨络铂衍生物及其药物组合物
AUPQ641100A0 (en) 2000-03-23 2000-04-15 Australia Nuclear Science & Technology Organisation Methods of synthesis and use of radiolabelled platinum chemotherapeutic ag ents
US7259270B2 (en) 2001-11-30 2007-08-21 Jingzun Wang Supermolecular carboplatin derivatives, their preparation and pharmaceutical composition containing them as active ingredient and applications of the compositions
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
CA2477923C (en) * 2002-03-01 2021-02-23 University Of South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
OA12905A (en) 2002-08-19 2006-10-13 Pfizer Prod Inc Combination therapy for hyperproliferative diseases.
WO2004099224A1 (de) * 2003-05-05 2004-11-18 Universität Regensburg Carboplatin-artige platin (ii)- komplexe
CN101146532B (zh) 2005-01-21 2012-05-09 阿斯泰克斯治疗有限公司 药物化合物
DK2049109T3 (en) 2006-08-02 2016-01-11 Sunesis Pharmaceuticals Inc Combined use of (+) - 1,4-dihydro-7 - [(3S, 4S) -3-methoxy-4- (methylamino) -1-pyrrolidinyl] -4-oxo-1- (2-thiazolyl) -1,8-naphthyridine-3-carboxylic acid and cytarabine (Ara-C) for the treatment of leukemia
BRPI0913485A2 (pt) 2008-09-15 2016-06-07 Kasina Laila Innova Pharmaceuticals Private Ltd medicamentos anticâncer e usos relacionados para melanoma maligno metastático e outros cânceres.
CZ302618B6 (cs) * 2009-09-10 2011-08-03 Univerzita Palackého Cyklobutan-1,1-dikarboxylátokomplexy platiny s deriváty N6-benzyladeninu, zpusoby jejich prípravy a použití techto komplexu jako léciv v protinádorové terapii
US20110287110A1 (en) 2010-04-23 2011-11-24 Mark Wesley Dewhirst Combination cancer treatment
KR102411227B1 (ko) 2013-10-17 2022-06-21 버텍스 파마슈티칼스 인코포레이티드 Dna-pk 억제제로서 (s)-n-메틸-8-(1-((2'-메틸-[4,5'-비피리미딘]-6-일)아미노)프로판-2-일)퀴놀린-4-카복스아미드 및 이의 듀테로화된 유도체의 공결정
CA2983411C (en) 2015-04-22 2023-02-21 Syn-Nat Products Enterprise LLC Co-crystal composition and its pharmaceutical use
EP3297624B1 (en) 2015-05-18 2021-03-03 Syn-Nat Products Enterprise LLC A pharmaceutical co-crystal and use thereof
EP3297440A4 (en) 2015-06-19 2019-04-10 Syn-Nat Products Enterprise LLC COMPOSITION WITH CARBOPLATIN AND USE

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090281319A1 (en) * 2006-01-30 2009-11-12 Platco Technologies (Proprietary) Limited Preparation of platinum (ii) complexes
WO2016205785A1 (en) * 2015-06-19 2016-12-22 Syn-Nat Products Enterprise LLC Pharmaceutical composition of carboplatin based co-crystals and use thereof
WO2016210418A1 (en) * 2015-06-25 2016-12-29 Syn-Nat Products Enterprise LLC Pharmaceutical co-crystal composition and use thereof

Also Published As

Publication number Publication date
JP2018521969A (ja) 2018-08-09
JP6851989B2 (ja) 2021-03-31
US10751318B2 (en) 2020-08-25
CN108135877A (zh) 2018-06-08
CN108135877B (zh) 2021-04-13
EP3297624B1 (en) 2021-03-03
EP3297624A4 (en) 2018-12-05
BR112017024727A2 (pt) 2018-07-31
KR20180008594A (ko) 2018-01-24
WO2016187191A1 (en) 2016-11-24
EP3297624A1 (en) 2018-03-28
US20180289662A1 (en) 2018-10-11
AU2016265922A1 (en) 2017-12-07
CA2986136A1 (en) 2016-11-24

Similar Documents

Publication Publication Date Title
AU2016265922B2 (en) A pharmaceutical co-crystal and use thereof
US11685757B2 (en) Pharmaceutical co-crystal composition and use thereof
JP5411847B2 (ja) Ｗｅｅｌキナーゼインヒビターとしてのジヒドロピラゾロピリミジノン誘導体の多形
CN103097367A (zh) 苯丙酸化合物、其制备方法及其医药用途
AU2016279099B2 (en) Pharmaceutical composition of carboplatin based co-crystals and use thereof
WO2015027669A2 (zh) 苯基取代化合物及其药物组合物和应用
WO2020224208A1 (zh) 吡啶酮衍生物的晶型及制备方法和应用
CN101381320A (zh) 一类具有曼尼希碱结构的化合物及在制备治疗和/或预防白血病药物上的应用
CN104387378B (zh) 4‑噻唑烷酮类衍生物及其应用
TWI324516B (en) Fused tri-heterocyclic compounds
CN101370813A (zh) 用作抗癌药物的6-[(取代的)苯基]三唑并嘧啶类的二聚体和加合物
HK40045137B (zh) Smad3抑制剂

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired